BML, Inc.
Stock Price Chart
2026/03/16 UpdatedPrice Trend
2026/03/16 UpdatedPrice & Trading Details
2026/03/16 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
MFS Series Trust V-MFS International New Discovery Fund
|
997.4K | +15.41% | |
|
HARTFORD MUTUAL FUNDS INC/CT-The Hartford International Value Fund
|
442.8K | -0.52% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
310.2K | +1.67% | |
|
Putnam Investment Funds-Putnam International Small Cap Fund
|
238.2K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
199.8K | +3.79% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
135.6K | 0.00% |
Dividend History 1Years Growth
Updated 2026/03/15| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥130 | +44.4% |
| 2024 | ¥90 | -10.0% |
| 2023 | ¥100 | -20.0% |
| 2022 | ¥125 | +47.1% |
| 2021 | ¥85 | - |
Financial Performance
2026/03/15 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥186,067M | ¥159,462M | ¥137,964M | ¥143,191M |
| Gross Profit | ¥86,951M | ¥61,446M | ¥45,628M | ¥45,861M |
| Operating Income | ¥48,890M | ¥23,937M | ¥9,167M | ¥9,364M |
| Pretax Income | ¥50,364M | ¥24,224M | ¥9,627M | ¥9,791M |
| Net Income | ¥33,741M | ¥15,578M | ¥6,034M | ¥6,263M |
| EPS | ¥832.62 | ¥395.62 | ¥154.74 | ¥160.55 |
| Operating Margin | 26.28% | 15.01% | 6.64% | 6.54% |
| Balance Sheet | ||||
| Total Assets | ¥179,200M | ¥168,943M | ¥170,991M | ¥177,507M |
| Total Equity | ¥116,196M | ¥122,488M | ¥125,864M | ¥129,400M |
| Total Liabilities | ¥63,004M | ¥46,455M | ¥45,127M | ¥48,107M |
| Cash | ¥92,126M | ¥86,521M | ¥74,114M | ¥67,562M |
| Interest-bearing Debt | ¥3,330M | ¥4,150M | ¥5,265M | ¥5,289M |
| Equity Ratio | 64.84% | 72.50% | 73.61% | 72.90% |
| D/E Ratio | 0.03 | 0.03 | 0.04 | 0.04 |
| Cash Flow | ||||
| Operating CF | ¥45,603M | ¥11,742M | ¥14,446M | ¥15,809M |
| Investing CF | -¥7,297M | -¥7,627M | -¥21,137M | -¥16,793M |
| Financing CF | -¥9,828M | -¥9,715M | -¥5,733M | -¥5,426M |
| Free CF | ¥38,518M | ¥5,282M | -¥6,481M | -¥849M |
| Efficiency | ||||
| ROE | 29.04% | 12.72% | 4.79% | 4.84% |
| ROA | 18.83% | 9.22% | 3.53% | 3.53% |
Latest IR Information
-
Notice of Partial Correction to the "Financial Summary for the Fiscal Year Ending March 2025 [Japanese GAAP] (Consolidated)"
Consolidated total assets for the fiscal year ending March 2025 have been corrected to JPY 182,873 million, net assets to JPY 133,772 million, and the equity ratio to 70.7%.
Read more -
Notice of Partial Correction to the Financial Summary for the Third Quarter Ended March 2026 (Japanese GAAP, Consolidated)
BML Inc. has corrected certain numerical data in the financial summary for the third quarter ended March 2026. Total assets have been revised to JPY 182,201 million and the equity ratio to 69.0%.
Read more -
Notice Regarding Submission of Amendment Reports for Past Years' Securities Reports and Corrections to Past Years' Financial Summaries
Due to errors in accounting treatment of retirement benefits, corrections were made to securities reports for the past five years and financial summaries for the past three years. Total assets increased by up to JPY 5,392 million, and the equity...
Read more -
Notice of Partial Correction to the Financial Summary for the First Quarter of the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)
Partial corrections were made to numerical data in the financial summary for the first quarter of the fiscal year ending March 2026. Total assets were revised to JPY 180,917 million, and the equity ratio was adjusted to 71.0%.
Read more -
Notice of Partial Correction to the Financial Summary for the Second Quarter of Fiscal Year Ending March 2026 (Interim) [Japanese GAAP] (Consolidated)
Correction of numerical data regarding the consolidated financial position in the financial summary for the second quarter of fiscal year ending March 2026. Total assets revised to 179,164 million yen, and equity ratio corrected to 70.1%.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,200
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
BML Revises First-Quarter 2024 Earnings Data After Discovering Numerical Errors - TipRanks ↗
Company Information
About
BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
